Allergy Patient Articles & Analysis
25 news found
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, ...
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut ...
This means that while some trees are related and pollens are somewhat similar, many tree pollens have unique features that prevent the ability to create a single treatment for tree pollen allergy. For this reason, allergists test sensitized patients for multiple different tree pollens and subsequently treat each patient uniquely for their ...
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. ...
Knowing the prevalence of food allergy makes it easier to understand the probability among the patients and helps easily rule out other uncommon diagnoses related to the symptoms presented by the patients. Most Common Types of Food Allergies There are a number of food allergies that are observed in ...
Notably, young children, especially toddlers, are at a higher risk of the potential for an anaphylactic shock due to food allergy, at a rate 5x that seen in adults[2]. Despite paying attention to ingredients used for cooking delicious traditional holiday meals, your loved ones with multiple food allergies will remain at high risk for allergic reactions due to ...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has ...
Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The independently conducted survey asked 270 healthcare professionals in the US (radiologists, oncologists and ...
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an initial update from its ongoing Phase 1 OMEGA Trial of INT301 in patients with peanut allergy. ...
Young-Suk Kim, head of business Merck Life Science business said, “Merck will support the process of a new bispecific protein drug of GI Innovation and aims to accelerate access to cancer and allergy drugs by patients around the world. We expect that we can supply required solution to solve problems across the board, a new drug development process to ...
“With the launch of #PeanutAllergyStrong, Intrommune invites patients, parents, and everyone affected by peanut allergies to share their ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
Rejoint has teamed up with the Fraunhofer Project Centre at the University of Twente in Netherlands, and the Fruanhofer Institute for Production Technology (IPT) in Aachen, Germany, in order to develop and validate a titanium tibial tray with an embedded lattice structure for accelerating the osseointegrative process of YourKnee, Rejoint's 3D printed patient-specific implant for TKR. It will ...
According to the American Academy of Asthma, Allergy and Immunology, an allergy to alpha-Gal can cause patients to have a severe and potentially life-threatening reaction to galactose-alpha-1, 3-galactose that is found in most mammalian (red) meat. ...
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. ...
OMIT enables regular administration of allergy immunotherapy to desensitize a patient to allergies while a user brushes their teeth. ...
With the total annual avoidable expenditure on the European allergy market, not limited to rhinitis, amounting between $50 billion and $150 billion, even back in 2014, Neurent Medical's out-patient device can help customers achieve significant savings by using RF in a highly targeted manner. ...
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. ...
An Irish company developing a breakthrough therapy for a common nasal condition has raised €9.3 million. Neurent Medical, based in Oranmore, Co Galway, is developing a medical device that would allow doctors treat patients with rhinitis in their offices, rather than in a surgical setting. The funding round was led by Fountain Healthcare Partners, the Irish life sciences fund. Others ...
The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of recombinant allergens. ...